ArticleLeukemia & lymphoma2025

CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.

Caspian Oliai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.